{"analyses":[{"ciLowerLimit":"0.47","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.83","groupDescription":"Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.00052","paramType":"Hazard Ratio (HR)","paramValue":"0.63","statisticalMethod":"Regression, Cox"},{"ciLowerLimit":"0.52","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.90","groupDescription":"Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1).","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.00358","paramType":"Hazard Ratio (HR)","paramValue":"0.69","statisticalMethod":"Regression, Cox"},{"ciLowerLimit":"0.67","ciPctValue":"95","ciUpperLimit":"1.22","groupDescription":"Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1).","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.51319","paramType":"Hazard Ratio (HR)","paramValue":"0.91","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.8","upperLimit":"64.0","value":"58.2"},{"groupId":"OG001","lowerLimit":"68.5","upperLimit":"78.9","value":"74.1"},{"groupId":"OG002","lowerLimit":"62.5","upperLimit":"73.6","value":"68.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"279"},{"groupId":"OG002","value":"277"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death due to any cause. The percentage of participants with OS (OS rate) at 12 months was reported for each arm. The reported percentage was estimated using a product-limit (Kaplan-Meier) method for censored data; data were censored at the date of cut-off. The primary analysis of OS was performed at the time of the second protocol pre-specified statistical analysis, with data cut-off of 03-Mar-2015.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).","id":"OG000","title":"Ipilimumab"},{"description":"Participants received pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.","id":"OG001","title":"Pembrolizumab Q2W"},{"description":"Participants received pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.","id":"OG002","title":"Pembrolizumab Q3W"}],"paramType":"NUMBER","populationDescription":"The ITT population, comprising all participants as randomized to a study arm.","reportingStatus":"POSTED","timeFrame":"Month 12","title":"Percentage of Participants With Overall Survival (OS) at 12 Months","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}